Evidence mapPaperPMID 40294356Full record

Trial reportJCO oncology practice2026

Promoting Resilience in Stress Management: A Randomized Controlled Trial of a Novel Psychosocial Intervention for Adolescents and Young Adults With Advanced Cancer.

Abby R Rosenberg, Kaitlyn M Fladeboe, Chuan Zhou, Miranda C Bradford, Tammy Kang, Scott Maurer, David R Freyer, K Scott Baker, Liam Comiskey, Courtney C Junkins and 2 more

Erratum issuedAbstract readRandomized Controlled TrialMulticenter Study
In one paragraph

Trial report in JCO oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Abby R RosenbergDepartment of Supportive Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-7608-607X
Kaitlyn M FladeboeBen Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children's Research Institute, Seattle, WA.ORCID 0000-0001-5434-7980
Chuan ZhouDepartment of Pediatrics, University of Washington, Seattle, WA.ORCID 0000-0002-2919-3593
Miranda C BradfordBiostatistics, Epidemiology and Analytics in Research Core, Seattle Children's Research Institute, Seattle, WA.ORCID 0000-0002-3385-0541
Tammy KangDepartment of Pediatrics, Texas Children's Hospital, Houston, TX.
Scott MaurerDepartment of Pediatrics, UPMC Children's Hospital, Pittsburgh, PA.
David R FreyerCancer and Blood Disease Institute, Children's Hospital of Los Angeles, Los Angeles, CA.ORCID 0000-0001-5280-990X
K Scott BakerDepartment of Pediatrics, University of Washington, Seattle, WA.
Liam ComiskeyDepartment of Supportive Oncology, Dana-Farber Cancer Institute, Boston, MA.
Courtney C JunkinsDepartment of Supportive Oncology, Dana-Farber Cancer Institute, Boston, MA.ORCID 0009-0002-3651-1040
Mallory R TaylorBen Towne Center for Childhood Cancer and Blood Disorders Research, Seattle Children's Research Institute, Seattle, WA.ORCID 0000-0002-8998-4530
Joyce P Yi-FrazierDepartment of Supportive Oncology, Dana-Farber Cancer Institute, Boston, MA.

Funding

NCI NIH HHS R01 CA222486
6 · The paper itself

Abstract

purposeAdolescents and young adults (AYAs) with advanced cancer (AC) report poor quality of life (QOL), high psychological distress, and minimal engagement in health care discussions. We assessed the effect of a novel resilience coaching program (Promoting Resilience in Stress Management [PRISM]-AC) on AYA outcomes.

methodsWe conducted a multisite randomized trial of PRISM-AC versus usual care (UC) among AYAs age 12-24 years, diagnosed with AC within 2 weeks before enrollment. PRISM-AC consists of four sessions targeting AYA-endorsed resilience resources (stress management, goal-setting, cognitive reframing, and meaning-making) plus a session integrating elements of advance care planning. Participants completed surveys at baseline, and 3, 6, 9, and 12 months. The primary outcome was Pediatric QOL at 3 months; secondary/exploratory outcomes included 3-month changes in resilience (10-item Connor-Davidson Resilience Scale) and hope (Snyder Hope Scale), and trajectories of QOL, anxiety, and depression (Hospital Anxiety and Depression Scale) over 12 months. We examined associations with linear mixed effects regression models. We also explored PRISM-AC's impact on AYA participation in critical health care discussions, as documented in the electronic health record.

resultsBetween April 2019 and January 2024, we enrolled 239 AYAs (56% of 426 approached) and randomly assigned 195 (82% of enrolled; 96 UC, 99 PRISM). They were of mean age 16.5 years (standard deviation, 3.9), mostly White (63%), non-Hispanic (59%), and publicly insured (53%). At 3 months, we detected no significant differences between groups with respect to QOL, anxiety, or depression; PRISM-AYAs demonstrated greater improvements in resilience (+1.3 [5.9]

conclusionAmong AYAs with AC, PRISM-AC did not immediately improve QOL. Rather, it improved resilience and hope, potentially enabling longer-term improvements in QOL.

Indexed as

NeoplasmsPsychosocial InterventionResilience, PsychologicalStress, PsychologicalAdolescentAdultChildFemaleHumansMaleQuality of LifeYoung Adult

Identifiers

PMID40294356
PMCPMC12788802

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.